Paracetamol (acetaminophen) use, fracture and bone mineral density

Lana J Williams; Julie A Pasco; Margaret J Henry; Kerrie M Sanders; Geoffrey C Nicholson; Mark A Kotowicz; Michael Berk

Journal article

Paracetamol (acetaminophen) use, fracture and bone mineral density

Lana J Williams, Julie A Pasco, Margaret J Henry, Kerrie M Sanders, Geoffrey C Nicholson, Mark A Kotowicz, Michael Berk

BONE | ELSEVIER SCIENCE INC | Published : 2011

DOI: 10.1016/j.bone.2011.03.435

Abstract

Paracetamol is the most widely prescribed simple analgesic and antipyretic. It exerts its effects via cyclooxygenase and endocannabinoid pathways, which may affect signalling in bone cells and hence influence bone metabolism. Given the high rates of paracetamol use in the community and the evidence linking its mechanism of action to bone metabolism, we aimed to investigate the association between paracetamol use, fracture, and bone mineral density (BMD) in women participating in the Geelong Osteoporosis Study (GOS). Cases (n = 569) were women aged ≥ 50 years identified from radiological reports as having sustained a fracture between 1994 and 1996. Controls (n = 775) were women without fractu..

View full abstract

University of Melbourne Researchers

Mark Kotowicz Author

Kerrie Sanders Author

Julie Pasco Author

Michael Berk Author Psychiatry

Related Projects (1)

Bone size and bone turnover: relationship to fracture risk over ten years

The occurrence of fracture in the ageing population is a major public health problem because these fractures are responsible for considerabl..

Grants

Awarded by National Health and Medical Research Council of Australia

Funding Acknowledgements

The study was funded by the National Health and Medical Research Council of Australia (#251638).Michael Berk has received Grant/Research Support from the Stanley Medical Research Foundation, MBF, NHMRC, Beyond Blue, Geelong Medical Research Foundation, Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline, Organon, Novartis, Mayne Pharma, Servier and Astra Zeneca. He has been a paid consultant for Astra Zeneca, Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline, Janssen Cilag, Lundbeck and Pfizer and a paid speaker for Astra Zeneca, Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline, Janssen Cilag, Lundbeck, Organon, Pfizer, Sanofi Synthelabo, Solvay and Wyeth.